NVCTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Nuvectis Pharma, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$18.94+0.34 (+1.83%)
Close on Oct 19, 2026
- Market cap
- $444.64M
- P/E (TTM)
- –
- Dividend yield
- 0.00%
Nuvectis Pharma statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Nuvectis Pharma | Industry median |
|---|---|---|
| Market Cap | $617.09M | $166.30M |
| Enterprise Value | $594.93M | $88.19M |
| PB Ratio | 67.95 | 2.03 |
| P/TBV Ratio | 67.95 | 2.29 |
Income (trailing twelve months)
| Measure | Nuvectis Pharma | Industry median |
|---|---|---|
| Operating Income | -$28.87M | -$21.40M |
| Net Income | -$27.85M | -$22.46M |
| EBITDA | -$28.87M | -$16.91M |
| EPS (Diluted) | -$1.32 | -$0.83 |
Returns
| Measure | Nuvectis Pharma | Industry median |
|---|---|---|
| Return on Equity (ROE) | -214.6% | -53.2% |
| Return on Assets (ROA) | -112.8% | -40.9% |
| Return on Capital Employed (ROCE) | -317.9% | -38.1% |
Balance sheet
| Measure | Nuvectis Pharma | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $22.16M | $61.43M |
| Net Cash (Debt) | $22.16M | $15.35M |
| Net Cash Per Share | $0.68 | $0.66 |
| Equity (Book Value) | $9.08M | $49.09M |
| Book Value Per Share | $0.28 | $1.37 |
| Tangible Book Value | $9.08M | $23.52M |
| Working Capital | $9.08M | $76.81M |
Financial position
| Measure | Nuvectis Pharma | Industry median |
|---|---|---|
| Current Ratio | 1.68 | 3.34 |
| Quick Ratio | 1.67 | 2.44 |
Cash flow (trailing twelve months)
| Measure | Nuvectis Pharma | Industry median |
|---|---|---|
| Operating Cash Flow | -$19.51M | -$12.35M |
Efficiency
| Measure | Nuvectis Pharma | Industry median |
|---|---|---|
| Profits Per Employee | -$2.14M | -$703.34K |
| Employee Count | 13 | 74 |
Dividends and yields
| Measure | Nuvectis Pharma | Industry median |
|---|---|---|
| Earnings Yield | -4.51% | -23.3% |
| Dividend Yield | 0.00% | 1.82% |
| Shareholder Yield | 0.00% | 0.00% |
| Dividend Per Share | $0.00 | $0.83 |
| Years of Dividend Growth | 0 | 0 |
Shares
| Measure | Nuvectis Pharma | Industry median |
|---|---|---|
| Shares Outstanding | 32,581,500 | 58,127,000 |
| Shares Change (YoY) | 21.6% | 10.9% |
| Shares Change (QoQ) | 0.64% | 0.54% |
| Float | 21,203,200 | 49,136,700 |
| Shares Held by Insiders | 34.9% | 11.6% |
| Shares Held by Institutions | 31.5% | 59.4% |
Scores
| Measure | Nuvectis Pharma | Industry median |
|---|---|---|
| Altman Z-Score | 17.03 | -0.22 |
| Piotroski F-Score | 3 | 4 |
Calculated by StockData from Nuvectis Pharma's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.